Revlimid gets OK in Europe for some patients with MDS

06/17/2013 |

The European Medicines Agency has approved the use of Celgene's Revlimid, or lenalidomide, in some myelodysplastic syndromes patients. The approval covers the use of the drug in patients with low- or intermediate-1-risk myelodysplastic syndrome and deletion 5q chromosomal abnormalities but no other chromo­somal ab­nor­mali­ties and who have become dependent on red blood cell transfusions and are not responding to other treatments.

View Full Article in:

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC